Journal Article DKFZ-2018-00074

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Drug-perturbation-based stratification of blood cancer.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2018
ASCJ Ann Arbor, Mich.

The journal of clinical investigation 128(1), 427 - 445 () [10.1172/JCI93801]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown. Here, we measured ex vivo sensitivity of 246 blood cancers to 63 drugs alongside genome, transcriptome, and DNA methylome analysis to understand determinants of drug response. We assembled a primary blood cancer cell encyclopedia data set that revealed disease-specific sensitivities for each cancer. Within chronic lymphocytic leukemia (CLL), responses to 62% of drugs were associated with 2 or more mutations, and linked the B cell receptor (BCR) pathway to trisomy 12, an important driver of CLL. Based on drug responses, the disease could be organized into phenotypic subgroups characterized by exploitable dependencies on BCR, mTOR, or MEK signaling and associated with mutations, gene expression, and DNA methylation. Fourteen percent of CLLs were driven by mTOR signaling in a non-BCR-dependent manner. Multivariate modeling revealed immunoglobulin heavy chain variable gene (IGHV) mutation status and trisomy 12 as the most important modulators of response to kinase inhibitors in CLL. Ex vivo drug responses were associated with outcome. This study overcomes the perception that most mutations do not influence drug response of cancer, and points to an updated approach to understanding tumor biology, with implications for biomarker discovery and cancer care.

Classification:

Contributing Institute(s):
  1. Translationale Onkologie (G100)
  2. Epigenomik und Krebsrisikofaktoren (C010)
  3. C060 Biostatistik (C060)
  4. DKTK Frankfurt (L501)
  5. B060 Molekulare Genetik (B060)
  6. Molekulare Therapie in der Hämatologie und Onkologie (G250)
  7. DKTK Freiburg (L601)
  8. DKTK Heidelberg (L101)
  9. DKTK Essen (L401)
Research Program(s):
  1. 317 - Translational cancer research (POF3-317) (POF3-317)

Appears in the scientific report 2018
Database coverage:
Medline ; BIOSIS Previews ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 10 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2018-02-07, last modified 2024-02-29



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)